Literature DB >> 34719806

Mass spectrometry-based targeted proteomics for analysis of protein mutations.

Tai-Tu Lin1, Tong Zhang1, Reta B Kitata1, Tao Liu1, Richard D Smith1, Wei-Jun Qian1, Tujin Shi1.   

Abstract

Cancers are caused by accumulated DNA mutations. This recognition of the central role of mutations in cancer and recent advances in next-generation sequencing, has initiated the massive screening of clinical samples and the identification of 1000s of cancer-associated gene mutations. However, proteomic analysis of the expressed mutation products lags far behind genomic (transcriptomic) analysis. With comprehensive global proteomics analysis, only a small percentage of single nucleotide variants detected by DNA and RNA sequencing have been observed as single amino acid variants due to current technical limitations. Proteomic analysis of mutations is important with the potential to advance cancer biomarker development and the discovery of new therapeutic targets for more effective disease treatment. Targeted proteomics using selected reaction monitoring (also known as multiple reaction monitoring) and parallel reaction monitoring, has emerged as a powerful tool with significant advantages over global proteomics for analysis of protein mutations in terms of detection sensitivity, quantitation accuracy and overall practicality (e.g., reliable identification and the scale of quantification). Herein we review recent advances in the targeted proteomics technology for enhancing detection sensitivity and multiplexing capability and highlight its broad biomedical applications for analysis of protein mutations in human bodily fluids, tissues, and cell lines. Furthermore, we review recent applications of top-down proteomics for analysis of protein mutations. Unlike the commonly used bottom-up proteomics which requires digestion of proteins into peptides, top-down proteomics directly analyzes intact proteins for more precise characterization of mutation isoforms. Finally, general perspectives on the potential of achieving both high sensitivity and high sample throughput for large-scale targeted detection and quantification of important protein mutations are discussed.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  alternative splicing variant; disease biomarker; fusion mutation; protein mutation; single amino acid polymorphism; single amino acid variant; targeted proteomics; top-down proteomics

Year:  2021        PMID: 34719806      PMCID: PMC9054944          DOI: 10.1002/mas.21741

Source DB:  PubMed          Journal:  Mass Spectrom Rev        ISSN: 0277-7037            Impact factor:   9.011


  162 in total

1.  High-efficiency nanoscale liquid chromatography coupled on-line with mass spectrometry using nanoelectrospray ionization for proteomics.

Authors:  Yufeng Shen; Rui Zhao; Scott J Berger; Gordon A Anderson; Nestor Rodriguez; Richard D Smith
Journal:  Anal Chem       Date:  2002-08-15       Impact factor: 6.986

Review 2.  The use of proteases complementary to trypsin to probe isoforms and modifications.

Authors:  Stéphane Trevisiol; Daniel Ayoub; Antoine Lesur; Lina Ancheva; Sébastien Gallien; Bruno Domon
Journal:  Proteomics       Date:  2016-03       Impact factor: 3.984

3.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.

Authors:  Qun Pan; Ofer Shai; Leo J Lee; Brendan J Frey; Benjamin J Blencowe
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

4.  Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease.

Authors:  Michael R Heaven; Landon Wilson; Stephen Barnes; Michael Brenner
Journal:  J Biol Chem       Date:  2019-09-04       Impact factor: 5.157

Review 5.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

Review 6.  Top-Down Proteomics: Ready for Prime Time?

Authors:  Bifan Chen; Kyle A Brown; Ziqing Lin; Ying Ge
Journal:  Anal Chem       Date:  2017-12-15       Impact factor: 6.986

Review 7.  PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.

Authors:  Zheng Yang; Lu Yu; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 8.  Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.

Authors:  Tujin Shi; Dian Su; Tao Liu; Keqi Tang; David G Camp; Wei-Jun Qian; Richard D Smith
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

9.  Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.

Authors:  Yongqian Shu; Xue Wu; Xiaoling Tong; Xiaonan Wang; Zhili Chang; Yu Mao; Xiaofeng Chen; Jing Sun; Zhenxin Wang; Zhuan Hong; Liangjun Zhu; Chunrong Zhu; Jun Chen; Ying Liang; Huawu Shao; Yang W Shao
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

10.  Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.

Authors:  Sushant Kumar; Declan Clarke; Mark B Gerstein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-28       Impact factor: 11.205

View more
  4 in total

1.  Proteogenomics and Differential Ion Mobility Enable the Exploration of the Mutational Landscape in Colon Cancer Cells.

Authors:  Zhaoguan Wu; Éric Bonneil; Michael Belford; Cornelia Boeser; Maria Virginia Ruiz Cuevas; Sébastien Lemieux; Jean-Jacques Dunyach; Pierre Thibault
Journal:  Anal Chem       Date:  2022-08-22       Impact factor: 8.008

2.  Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study.

Authors:  Tânia Lima; António S Barros; Fábio Trindade; Rita Ferreira; Adelino Leite-Moreira; Daniela Barros-Silva; Carmen Jerónimo; Luís Araújo; Rui Henrique; Rui Vitorino; Margarida Fardilha
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

3.  The molecular mechanism of Ligusticum wallichii for improving idiopathic pulmonary fibrosis: A network pharmacology and molecular docking study.

Authors:  Xiaozheng Wu; Wen Li; Zhenliang Luo; Yunzhi Chen
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

4.  Comparative proteomic and clinicopathological analysis of breast adenoid cystic carcinoma and basal-like triple-negative breast cancer.

Authors:  Qian Yao; Wei Hou; Junbing Chen; Yanhua Bai; Mengping Long; Xiaozheng Huang; Chen Zhao; Lixin Zhou; Dongfeng Niu
Journal:  Front Med (Lausanne)       Date:  2022-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.